Brainstorm Cell Therapeutics(BCLI)2025-03-31 11:10Financial Performance - For the fiscal year ended December 31, 2024, BrainStorm reported a net loss of approximately $11.6 million, a decrease from a net loss of approximately $17.2 million in 2023, representing a 32% improvement[9]. - Research and development expenditures for 2024 were $4.7 million, down from $10.7 million in 2023, indicating a 56% reduction in R&D spending[9]. - General and administrative expenses decreased to approximately $7.0 million in 2024 from $10.7 million in 2023, reflecting a 35% reduction[9]. - Cash and cash equivalents were approximately $0.4 million as of December 31, 2024, down from $1.5 million at the end of 2023[9]. Clinical Trials and Partnerships - The company is preparing for a Phase 3b trial of NurOwn, which will involve approximately 200 participants with ALS, having secured a Special Protocol Assessment (SPA) agreement with the FDA[2]. - A strategic partnership with Pluri was announced to support manufacturing for the Phase 3b NurOwn trial, enhancing operational readiness[8]. Funding and Compliance - BrainStorm has entered into a warrant inducement agreement expected to raise approximately $1.64 million, anticipated to close on or about April 1, 2025[6]. - The company regained compliance with Nasdaq's minimum bid price requirement on October 30, 2024, ensuring continued listing on the Nasdaq Capital Market[8]. Intellectual Property and Research Findings - BrainStorm received a Notice of Allowance for a new patent covering exosome platform technology, strengthening its intellectual property portfolio[5]. - The company presented findings at the 2024 NEALS Meeting, showing a statistically significant survival benefit for ALS patients treated with NurOwn[8].